US Flu Vaccine Market to Reach USD 3 Bn by 2024, Expects DPI Research in Its New Report Now Available at MarketPublishers.com11 Sep 2017 • by Natalie Aster
LONDON – Driven by constantly increasing disease awareness, favourable initiatives introduced by the country’s government and advisory bodies to increase awareness about vaccination as well as introduction of quadrivalent flu vaccine, the US flu vaccine market is projected to see robust growth and reach appr. USD 3 billion in value by 2024. By 2024, the number of people vaccinated with flu vaccines in the US is predicted to increase to 185 million.
New topical research publication “Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024” prepared by DPI Research & Marketing Solutions presents a profound evaluation of the US market for flu vaccines. It scrutinizes the flu vaccination patterns in both adult and children sectors, uncovers reliable statistics on the flu vaccines production and consumption, reviews the key distribution channels and touches upon the price fluctuations. Furthermore, this topical report describes the regulatory framework, features reimbursement patterns, comprises assessment of clinical trials and reviews promising flu vaccines in the clinical development. Moreover, top trends and the recent business activities in this field are covered. This report provides comprehensive profiles of the dominant players in the country’s flu vaccine market such as GSK, Seqirus and Sanofi Pasteur with important details on companies’ products, sales, strategies and the latest developments. Besides, the report offers a detailed analysis of the US flu vaccine market landscape, examines the main market growth driving and restraining forces, and also gives an all-round future outlook through 2024.
Flu vaccines covered in this topical publication include: Fluzone High–Dose, Intradermal (ID) Trivalent, Fluzone Quadrivalent, Vaxigrip, Afluria Quadrivalent, Fluarix Quadrivalent, Agrippal, Flulaval Quadrivalent, Fluvirin, Flucelvax Quadrivalent, Fluvax and Fluad.
Many other in-demand research reports worked out by this publisher are provided in the DPI Research & Marketing Solutions catalogue.